https://catalyst-hm.com
America/New_York
America/New_York
America/New_York
20231105T020000
-0400
-0500
EST
20240310T020000
-0500
-0400
EDT
ai1ec-205621@catalyst-hm.com
20240329T071024Z
Summit Meetings
CATALYST: Insights from the Experts to Navigate a Complex and Evolving Landscape in CLL and AML Management
Date: Wednesday, October 6, 2021
Time: 7:00 PM – 9:00 PM EST
To pre-register for the live event, please visit www.MLG-HM.com or call 1-207-847-0613
20211006T190000
20211006T210000
0
CATALYST: Insights from the Experts to Navigate a Complex and Evolving Landscape in CLL and AML Management
free
thumbnail;https://catalyst-hm.com/wp-content/uploads/2021/09/HM_21_02L_banner-150x150.jpg;150;150;1,medium;https://catalyst-hm.com/wp-content/uploads/2021/09/HM_21_02L_banner-300x46.jpg;300;46;1,large;https://catalyst-hm.com/wp-content/uploads/2021/09/HM_21_02L_banner-1024x157.jpg;1024;157;1,full;https://catalyst-hm.com/wp-content/uploads/2021/09/HM_21_02L_banner.jpg;1220;187;
ai1ec-205642@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Thursday, October 21, 2021
9:00PM – 10:00PM ET
Please note this TeleECHO Session is 9:00PM Eastern, 8:00PM Central, 7:00PM Mountain and 6:00PM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20211021T210000
20211021T220000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205636@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Friday, October 22, 2021
3:00PM – 4:00PM ET
Please note this TeleECHO program is 3:00PM Eastern, 2:00PM Central, 1:00PM Mountain and 12:00PM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20211022T150000
20211022T160000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205643@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Wednesday, October 27, 2021
12:00PM – 1:00PM ET
Please note this TeleECHO program is 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain and 9:00AM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20211027T120000
20211027T130000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205644@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Friday, October 29, 2021
3:00PM – 4:00PM ET
Please note this TeleECHO program is 3:00PM Eastern, 2:00PM Central, 1:00PM Mountain and 12:00PM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20211029T150000
20211029T160000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205645@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Wednesday, November 3, 2021
6:00PM – 7:00PM ET
Please note this TeleECHO program is 6:00PM Eastern, 5:00PM Central, 4:00PM Mountain and 3:00PM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20211103T180000
20211103T190000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205646@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Wednesday, November 10, 2021
7:00PM – 8:00PM ET
Please note this TeleECHO program is 7:00PM Eastern, 6:00PM Central, 5:00PM Mountain and 4:00PM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20211110T190000
20211110T200000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205647@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Tuesday, November 16, 2021
12:00PM – 1:00PM ET
Please note this TeleECHO program is 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain and 9:00AM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20211116T120000
20211116T130000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205649@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Thursday, December 2, 2021
6:00PM – 7:00PM ET
Please note this TeleECHO program is 6:00PM Eastern, 5:00PM Central, 4:00PM Mountain and 3:00PM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20211202T180000
20211202T190000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205650@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Tuesday, December 7, 2021
9:00PM – 10:00PM ET
Please note this TeleECHO program is 9:00PM Eastern, 8:00PM Central, 7:00PM Mountain and 6:00PM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20211207T210000
20211207T220000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205687@catalyst-hm.com
20240329T071024Z
Booth,New York
2021 ASH Annual Meeting
Location
Georgia World Congress Center
285 Andrew Young Int’l Blvd. NW
Atlanta, GA 30313
Booth 2471
VISIT OUR VIRTUAL REALITY ROOM – EXHIBIT HALL HOURS
Saturday, December 11, 2021 ~ 11:00 AM – 5:00 PM
Sunday, December 12, 2021 ~ 10:00 AM – 5:00 PM
Monday, December 13, 2021 ~ 10:00 AM – 2:00 PM
20211211T110000
20211213T140000
Georgia World Congress Center
0
2021 ASH Annual Meeting
free
ai1ec-205651@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Thursday, December 15, 2021
6:00PM – 7:00PM ET
Please note this TeleECHO program is 6:00PM Eastern, 5:00PM Central, 4:00PM Mountain and 3:00PM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20211215T180000
20211215T190000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205652@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Monday, January 10, 2022
12:00PM – 1:00PM ET
Please note this TeleECHO program is 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain and 9:00AM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20220110T120000
20220110T130000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205653@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Wednesday, January 12, 2022
3:00PM – 4:00PM ET
Please note this TeleECHO program is 3:00PM Eastern, 2:00PM Central, 1:00PM Mountain and 12:00PM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20220112T150000
20220112T160000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205654@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Thursday, January 20, 2022
7:00PM – 8:00PM ET
Please note this TeleECHO program is 7:00PM Eastern, 6:00PM Central, 5:00PM Mountain and 4:00PM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20220120T190000
20220120T200000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205655@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Saturday, January 22, 2022
10:00AM – 11:00AM ET
Please note this TeleECHO program is 10:00AM Eastern, 9:00AM Central, 8:00AM Mountain and 7:00AM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20220122T100000
20220122T110000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205656@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Wednesday, January 26, 2022
12:00PM – 1:00PM ET
Please note this TeleECHO program is 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain and 9:00AM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20220126T120000
20220126T130000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205657@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Tuesday, February 1, 2022
3:00PM – 4:00PM ET
Please note this TeleECHO program is 3:00PM Eastern, 2:00PM Central, 1:00PM Mountain and 12:00PM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20220201T150000
20220201T160000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205659@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Thursday, February 3, 2022
6:00PM – 7:00PM ET
Please note this TeleECHO program is 6:00PM Eastern, 5:00PM Central, 4:00PM Mountain and 3:00PM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20220203T180000
20220203T190000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205660@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Monday, February 7, 2022
3:00PM – 4:00PM ET
Please note this TeleECHO program is 3:00PM Eastern, 2:00PM Central, 1:00PM Mountain and 12:00PM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20220207T150000
20220207T160000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205661@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Wednesday, February 9, 2022
6:00PM – 7:00PM ET
Please note this TeleECHO program is 6:00PM Eastern, 5:00PM Central, 4:00PM Mountain and 3:00PM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20220209T180000
20220209T190000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205662@catalyst-hm.com
20240329T071024Z
TeleECHOs
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
REGISTER FOR ECHO SESSION
Saturday, February 12, 2022
9:00AM – 10:00AM ET
Please note this TeleECHO program is 9:00AM Eastern, 8:00AM Central, 7:00AM Mountain and 6:00AM Pacific.
PROGRAM OVERVIEW
This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
Presenting Faculty:
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
Learning Objectives
After completing the CME activity, learners should be better able to:
Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Target Audience
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
Credits:
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR ECHO SESSION
20220212T090000
20220212T100000
0
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
free
thumbnail;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,medium;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,large;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239,full;https://406hhe1esqm3307ujn1uhsj9-wpengine.netdna-ssl.com/wp-content/uploads/2021/09/HM_26L_banner.jpg;1383;239
ai1ec-205754@catalyst-hm.com
20240329T071024Z
Summit Meetings
CATALYST: Enhancing Clinical Decision-Making and Optimizing Health Outcomes in Hematologic Malignancies
REGISTER FOR LIVE CME PROGRAM
Wednesday, October 19, 2022
6:00 PM – 8:00 PM EDT
Virtual Symposium live at: 6:00 PM Eastern; 5:00 PM Central; 4:00 PM Mountain; 3:00 PM Pacific
FACULTY
Michael R. Grunwald, MD
Chief, Leukemia Division
Director, Transplantation and Cellular Therapy Program
Levine Cancer Institute, Atrium Health
Charlotte, NC
Ryan Jacobs, MD
Principle Investigator of CLL Clinical Trials
Department of Hematology, Lymphoma Division
Assistant Professor of Medicine
Levine Cancer Institute, Atrium Health
Charlotte, NC
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
Summarize the relevance of molecular markers and genetic data relevant to selection of therapy in CLL or AML
Review relevant treatment best practices in both newly diagnosed and relapsed/refractory AML in consideration of disease- and patient-specific factors to inform shared decision-making
Evaluate potential adverse events associated CLL and AML therapies to implement appropriate monitoring and counseling
TARGET AUDIENCE
This virtually live activity is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with CLL and/or AML.
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with CLL and/or AML.
CNE Credits: 2.0 ANCC Contact Hours
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 2.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITY ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
REGISTER FOR LIVE CME PROGRAM
20221019T180000
20221019T200000
0
CATALYST: Enhancing Clinical Decision-Making and Optimizing Health Outcomes in Hematologic Malignancies
free
thumbnail;https://catalyst-hm.com/wp-content/uploads/2022/10/HM_33_banner_footer.final_-150x150.jpg;150;150;1,medium;https://catalyst-hm.com/wp-content/uploads/2022/10/HM_33_banner_footer.final_-300x46.jpg;300;46;1,large;https://catalyst-hm.com/wp-content/uploads/2022/10/HM_33_banner_footer.final_-1024x157.jpg;1024;157;1,full;https://catalyst-hm.com/wp-content/uploads/2022/10/HM_33_banner_footer.final_.jpg;1220;187;
ai1ec-205919@catalyst-hm.com
20240329T071024Z
Booth
Visit our Virtual Reality Room at Booth 755!
Exhibit Hall Hours:
December 9: 11:00 am – 5:00 pm
December 10: 10:00 am – 5:00 pm
December 11: 10:00 am – 2:00 pm
20231209T110000
20231211T140000
0
ASH Annual Meeting 2023
free